Glucagon and Type 2 Diabetes: the Return of the Alpha Cell

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2014 Oct 27

PMID 25344790

Citations 48

Authors

Asger Lund

Jonatan I Bagger

Mikkel Christensen

Filip K Knop

Tina Vilsboll

Affiliations

Soon will be listed here.

Abstract

In normal physiology, glucagon from pancreatic alpha cells plays an important role in maintaining glucose homeostasis via its regulatory effect on hepatic glucose production. Patients with type 2 diabetes suffer from fasting and postprandial hyperglucagonemia, which stimulate hepatic glucose production and, thus, contribute to the hyperglycemia characterizing these patients. Although this has been known for years, research focusing on alpha cell (patho)physiology has historically been dwarfed by research on beta cells and insulin. Today the mechanisms behind type 2 diabetic hyperglucagonemia are still poorly understood. Preclinical and clinical studies have shown that the gastrointestinal hormone glucose-dependent insulinotropic polypeptide (GIP) might play an important role in this pathophysiological phenomenon. Furthermore, it has become apparent that suppression of glucagon secretion or antagonization of the glucagon receptor constitutes potentially effective treatment strategies for patients with type 2 diabetes. In this review, we focus on the regulation of glucagon secretion by the incretin hormones glucagon-like peptide-1 (GLP-1) and GIP. Furthermore, potential advantages and limitations of suppressing glucagon secretion or antagonizing the glucagon receptor, respectively, in the treatment of patients with type 2 diabetes will be discussed.

Citing Articles

Hepatic Metabolic Memory Triggered by AM Exposure to Glucagon Alters Afternoon Glucose Metabolism.

Waterman H, Smith M, Farmer B, Yankey K, Howard T, Kraft G bioRxiv. 2025; .

PMID: 40060516 PMC: 11888283. DOI: 10.1101/2025.02.25.639957.

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus.

He X, Zhao W, Li P, Zhang Y, Li G, Su H Front Pharmacol. 2025; 15:1483792.

PMID: 39902077 PMC: 11788294. DOI: 10.3389/fphar.2024.1483792.

Hyperglucagonemia and glucagon hypersecretion in early type 2 diabetes result from multifaceted dysregulation of pancreatic mouse α-cells.

Ruiz-Pino A, Goncalves-Ramirez A, Jimenez-Palomares M, Merino B, Castellano-Munoz M, Vettorazzi J Pflugers Arch. 2024; 477(2):207-221.

PMID: 39601887 DOI: 10.1007/s00424-024-03045-5.

Hesperidin activates the GLP-1R/cAMP-CREB/IRS2/PDX1 pathway to promote transdifferentiation of islet α cells into β cells Across the spectrum.

Zhang W, Wu L, Qu R, Liu T, Wang J, Tong Y Heliyon. 2024; 10(16):e35424.

PMID: 39220963 PMC: 11365324. DOI: 10.1016/j.heliyon.2024.e35424.

Gut Microbiota in the Progression of Type 2 Diabetes and the Potential Role of Exercise: A Critical Review.

Deli C, Fatouros I, Poulios A, Liakou C, Draganidis D, Papanikolaou K Life (Basel). 2024; 14(8).

PMID: 39202758 PMC: 11355287. DOI: 10.3390/life14081016.

References

Adrian T, Bloom S, Hermansen K, Iversen J . Pancreatic polypeptide, glucagon and insulin secretion from the isolated perfused canine pancreas. Diabetologia. 1978; 14(6):413-7. DOI: 10.1007/BF01228136. View

Ahren B . Autonomic regulation of islet hormone secretion--implications for health and disease. Diabetologia. 2000; 43(4):393-410. DOI: 10.1007/s001250051322. View

Unger R, Orci L . The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1975; 1(7897):14-6. DOI: 10.1016/s0140-6736(75)92375-2. View

Ding W, Renstrom E, Rorsman P, Buschard K, Gromada J . Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes. 1997; 46(5):792-800. DOI: 10.2337/diab.46.5.792. View

Reaven G, Chen Y, Golay A, Swislocki A, Jaspan J . Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987; 64(1):106-10. DOI: 10.1210/jcem-64-1-106. View

Knop F, Vilsboll T, Madsbad S, Holst J, Krarup T . Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia. 2007; 50(4):797-805. DOI: 10.1007/s00125-006-0566-z. View

Meier J, Deacon C, Schmidt W, Holst J, Nauck M . Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia. 2007; 50(4):806-13. DOI: 10.1007/s00125-007-0598-z. View

Raju B, Cryer P . Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes. 2005; 54(3):757-64. DOI: 10.2337/diabetes.54.3.757. View

Holst J, Vilsboll T, Deacon C . The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2008; 297(1-2):127-36. DOI: 10.1016/j.mce.2008.08.012. View

10.

Edwards C, Todd J, Mahmoudi M, Wang Z, Wang R, Ghatei M . Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999; 48(1):86-93. DOI: 10.2337/diabetes.48.1.86. View

11.

Holst J, Deacon C . Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005; 48(4):612-5. DOI: 10.1007/s00125-005-1705-7. View

12.

Lee Y, Wang M, Du X, Charron M, Unger R . Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes. 2011; 60(2):391-7. PMC: 3028337. DOI: 10.2337/db10-0426. View

13.

Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N . Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab. 2006; 3(1):47-58. DOI: 10.1016/j.cmet.2005.11.015. View

14.

Chia C, Carlson O, Kim W, Shin Y, Charles C, Kim H . Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes. 2009; 58(6):1342-9. PMC: 2682676. DOI: 10.2337/db08-0958. View

15.

Shah P, Vella A, Basu A, Basu R, Schwenk W, Rizza R . Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000; 85(11):4053-9. DOI: 10.1210/jcem.85.11.6993. View

16.

Gedulin B, Rink T, Young A . Dose-response for glucagonostatic effect of amylin in rats. Metabolism. 1997; 46(1):67-70. DOI: 10.1016/s0026-0495(97)90170-0. View

17.

Dupre J, Caussignac Y, McDonald T, van Vliet S . Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia. J Clin Endocrinol Metab. 1991; 72(1):125-9. DOI: 10.1210/jcem-72-1-125. View

18.

Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I . Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991; 260(1 Pt 1):E67-74. DOI: 10.1152/ajpendo.1991.260.1.E67. View

19.

Nauck M, Schmidt W, Ebert R, Strietzel J, Cantor P, Hoffmann G . Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab. 1989; 69(3):654-62. DOI: 10.1210/jcem-69-3-654. View

20.

PEDERSON R, Brown J . Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology. 1978; 103(2):610-5. DOI: 10.1210/endo-103-2-610. View